Your session is about to expire
← Back to Search
Mepolizumab for Churg-Strauss Syndrome
Study Summary
This trial is for a potential new treatment for a rare disorder called EGPA, which is characterized by high levels of a certain type of white blood cell. The new treatment, mepolizumab, is given as an injection every 4 weeks and is designed to help regulate the life-cycle of the white blood cells. The trial is designed to see if the treatment is effective and safe.
- Churg-Strauss Syndrome
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 136 Patients • NCT02020889Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Mepolizumab is most often associated with which medical condition?
"While ulcerative colitis is the primary condition that mepolizumab is used to treat, this medication can also be used to manage varicella-zoster virus acute retinal necrosis, brain, and inflamed external hemorrhoid."
Are there numerous research centers administering this trial in Canada?
"Currently, there are 14 active clinical trial sites for this medication, with locations in New york, Cleveland, Saint Louis, and other US cities. If you are selected for the trial, the site administrator will try to place you at the location nearest to you to minimize travel."
How many participants will be included in this clinical research?
"At this time, this particular clinical trial is not recruiting any more patients. It was initially posted on April 14th, 2015 but the most recent update was on July 5th, 2022. For those searching for other trials, there are 11 trials recruiting patients with churg-strauss syndrome and 107 trials for Mepolizumab that are still enrolling patients."
When did the FDA last give their opinion on mepolizumab?
"Mepolizumab is estimated to be a safe medication because it is in Phase 3 clinical trials. In these types of trials, there is data supporting the efficacy of the medication as well as multiple rounds of data supporting safety."
Share this study with friends
Copy Link
Messenger